On December 9, 2024, Merck announced topline data from the Phase 3 KEYLYNK-001 trial, evaluating Keytruda plus chemotherapy followed by maintenance with Lynparza, with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer.
The trial met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. However, the study missed its other primary endpoint of overall survival (OS).
These mixed results indicate that while the combination therapy may delay disease progression, it did not extend patients' lives significantly. A full evaluation of the study data is ongoing, which will inform future development and regulatory strategies for this combination.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.